The Food and Drug Administration approved the first ever weed-based prescription medication on Monday. The drug, called Epidiolex, isn’t meant to get you stoned, but rather works to curb seizures in those with an extreme form of childhood epilepsy.

The drug itself is made from cannabidiol, more commonly known as CBD, which is part of the cannabis plant. Unlike THC, which is responsible for the mind-altering effects commonly associated with weed, CBD properties are more curative and calming. However, the FDA’s explicit approval of the substance lends it a credence that extends beyond labels.

“The FDA will continue to support rigorous scientific research on potential medical treatments using marijuana and its components that seek to be developed through the appropriate scientific channels,” said FDA Commissioner Scott Gottlieb in a statement on Monday. “However, we remain concerned about the proliferation and illegal marketing of unapproved CBD-containing products with unproven medical claims.” Thanks to the marijuana’s general illegality, trusted suppliers of medical grade CBD oil are generally hard to come by. A deluge of products claim to contain certain amount of CBD, but without clear regulatory standards, the dosage accuracy is difficult to confirm.

FDA approval aside, Epidiolex’s path to the market will likely be long and complicated. The Drug Enforcement Agency (DEA) still considers marijuana to be a Schedule I substance on the level of heroin, LSD, or magic mushrooms. Despite multiple appeals for declassification, cannabis has remained under lock and key over the years, which has held up academic and medicinal research on its potential to help sick people.

Though some states within the US have legalized recreational and medicinal marijuana, proper research on the plant is extremely difficult to conduct. Epidiolex’s approval could change that.